Products
Imidapril is registered as a powder for oral solution (Prilium). It has been approved in many countries since 2004. Imidapril has also been used in humans, but no human medicines are currently registered in many countries (Tanatril).
Structure and properties
Imidapril (C20H27N3O6, Mr = 405.4 g/mol) is a prodrug and is biotransformed by ester hydrolysis to the active metabolite imidaprilat. It is present in the drug as imidapril hydrochloride.
Effects
Imidapril (ATCvet QC09AA16) is antihypertensive and lowers preload and afterload. Its effects are due to inhibition of the formation of angiotensin II from angiotensin I by inhibition of angiotensin converting enzyme (ACE). Imidapril thus abolishes the effects of antiogensin II.
Indications
Imidapril is used to treat heart failure in dogs.
Dosage
According to the SmPC. The solution is administered to the dog once daily directly into the mouth or together with a small amount of food. The active ingredient is best absorbed when the dog is fasting.
Contraindications
Imidapril is contraindicated in hypersensitivity, hypotension, or acute renal failure. It should not be administered to pregnant animals. For complete precautions, see the drug label.
Interactions
Drug-drug interactions have been described with diuretics and a low-salt diet.
Adverse effects
Possible adverse effects include diarrhea, low blood pressure, fatigue, dizziness, and loss of appetite.
